Wittekind Amends Renovaro Inc. (RNV) Stake in SC 13D/A Filing

Ticker: LNAI · Form: SC 13D/A · Filed: Feb 16, 2024 · CIK: 1527728

Renovaro Inc. SC 13D/A Filing Summary
FieldDetail
CompanyRenovaro Inc. (LNAI)
Form TypeSC 13D/A
Filed DateFeb 16, 2024
Risk Levellow
Pages11
Reading Time13 min
Key Dollar Amounts$0.0001, $20,000,000
Sentimentneutral

Sentiment: neutral

Topics: insider-ownership, amendment, beneficial-ownership

TL;DR

**Wittekind just updated his stake in Renovaro Inc. (RNV) via an SC 13D/A, keep an eye on it.**

AI Summary

William Anderson Wittekind filed Amendment No. 14 to Schedule 13D for Renovaro Inc. (formerly Enochian Biosciences Inc.), indicating a change in his beneficial ownership. The filing, dated February 16, 2024, updates previous disclosures regarding his holdings in the company's Common Stock, par value $0.0001. This amendment reflects ongoing adjustments to his investment position in the pharmaceutical preparations company.

Why It Matters

This filing provides updated transparency on a significant shareholder's position in Renovaro Inc., which can influence investor perception and potentially the company's stock performance.

Risk Assessment

Risk Level: low — This is an amendment to a beneficial ownership report, which is a routine disclosure and does not inherently signal high risk.

Key Numbers

  • 14 — Amendment Number (Indicates multiple prior filings by the same beneficial owner)
  • 0001527728 — Renovaro Inc. CIK (Unique identifier for the subject company)
  • 0001753085 — William Anderson Wittekind CIK (Unique identifier for the filing person)

Key Players & Entities

  • William Anderson Wittekind (person) — Filing person, beneficial owner
  • Renovaro Inc. (company) — Subject company, Issuer
  • Enochian Biosciences Inc. (company) — Former name of Renovaro Inc.
  • 03 Life Sciences (company) — Organization name associated with Renovaro Inc.
  • $0.0001 (dollar_amount) — Par value of Common Stock
  • February 16, 2024 (date) — Filing date

FAQ

Who filed this SC 13D/A Amendment No. 14?

William Anderson Wittekind filed this SC 13D/A Amendment No. 14.

What is the subject company of this filing?

The subject company is Renovaro Inc., formerly known as Enochian Biosciences Inc. and Renovaro Biosciences Inc.

What is the CUSIP number for the class of securities involved?

The CUSIP number for the Common Stock, par value $0.0001, is 29350E 104.

When was this amendment filed?

This amendment was filed on February 16, 2024.

What is the business phone number listed for Renovaro Inc.?

The business phone number listed for Renovaro Inc. is 45 39179840.

Filing Stats: 3,290 words · 13 min read · ~11 pages · Grade level 12.7 · Accepted 2024-02-16 18:11:03

Key Financial Figures

  • $0.0001 — ame of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 29350
  • $20,000,000 — the purchaser under the Issuer’s $20,000,000 equity lines of credit signed on June 2

Filing Documents

Purpose of Transaction

Item 4. Purpose of Transaction The information in Item 6 of this Amendment No. 14 is hereby incorporated by reference into this Item 4.

Interests in Securities

Item 5. Interests in Securities of the Issuer (a)-(b) The information in Items 7-11 and Item 13 of the cover page of this Amendment No. 13, including the accompanying footnotes, is hereby incorporated by reference into this Item 5. (c) None. (d) Not applicable. (e) Not applicable.

. Contracts, Arrangements, Understandings

Item 6 . Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. GEDi Cube Acquisition On February 14, 2024 the Issuer filed a Form 8-K reporting that it completed its acquisition of GEDi Cube Intl Ltd. (“ GEDi Cube ”) pursuant to that certain Stock Purchase Agreement dated September 28, 2023 by and among the Issuer, GEDi Cube shareholders party thereto as sellers, and Yalla Yalla Ltd. in its capacity as the sellers’ representative (the “ Stock Purchase Agreement ”). According to the Issuer’s Form 8-K and its Form 10-Q filed on February 14, 2024, due to the Issuer’s issuance of 70,834,183 shares of Common Stock pursuant to the Stock Purchase Agreement, the number of issued and outstanding shares of Common Stock was increased from 67,224,089 to 143,668,372. As a result, the beneficial ownership of the Reporting Person decreased from approximately 28.4% (as of the date of Amendment No. 13) to approximately 13.2%. 3 The Special Meeting of Stockholders According to the Issuer’s Form 8-K filed on January 25, 2024, the Issuer held the special meeting of stockholders (“ Special Meeting ”) described in the Issuer’s proxy the Issuer sought stockholder approval at the Special Meeting to amend its Certificate of Incorporation to increase the number of authorized shares of Common Stock to a number sufficient to issue shares to the GEDi Cube shareholders under the Stock Purchase Agreement. According to the Issuer’s press release attached to the Form 8-K filed on January 25, 2024, all matters put before the Issuer’s stockholders for consideration and approval at the Special Meeting were approved by the requisite number of votes cast at the Special Meeting. Stockholder Derivative Complaint On January 23, 2024 Weird Science an

Material to be Filed as Exhibits

Item 7. Material to be Filed as Exhibits Exhibit 12 Verified Stockholder Derivative Complaint filed in the United States District Court for the Central District of California – Western Division on January 23, 2024. Exhibit 13 Ex Parte Application for Temporary Restraining Order and Order to Show Cause Why a Preliminary Injunction Should Not Issue filed in the United States District Court for the Central District of California – Western Division on January 23, 2024. Exhibit 14 Opposition to Ex Parte Application for Temporary Restraining Order and Order to Show Cause Why a Preliminary Injunction Should Not Issue filed in the United States District Court for the Central District of California – Western Division on January 24, 2024. Exhibit 15 Order of the United et al. , dated January 24, 2024. Exhibit 16 First Amended Verified Complaint filed with the Delaware Chancery Court on December 4, 2023. 8 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Amendment No. 14 is true, complete and correct. Date: February 16, 2024 /s/ William Anderson Wittekind WILLIAM ANDERSON WITTEKIND 9

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.